Grazoprevir Hydrate/Ruzasvir/Uprifosbuvir

N/A

Report date: 2023/04/13 17:55:51

Base Information

Drug NameGrazoprevir Hydrate/Ruzasvir/Uprifosbuvir
Drug Alias NameGrazoprevir Hydrate/Uprifosbuvir/RuzasvirUprifosbuvir/ruzasvir/grazoprevirUprifosbuvir/grazoprevir/ruzasvirRuzasvir/uprifosbuvir/grazoprevirRuzasvir/grazoprevir/uprifosbuvir +[16] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives
Mechanisms of ActionNonstructural protein 5A inhibitorsHepatitis C virus NS5B RNA-dependent RNA polymerase inhibitorsHepatitis C virus serine protease, NS3/NS4A inhibitors
TargetsHepatitis C virus NS5B RNA-dependent RNA polymeraseNonstructural protein 5AHepatitis C virus serine protease, NS3/NS4A
Therapy Area/IndicationsHepatitis C
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes UprifosbuvirGrazoprevir HydrateRuzasvir
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMerck & Co Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMerck Sharp & Dohme LLC
Active IndicationsN/A
Inactive IndicationsHepatitis C

Other Information

ATC CodeN/A
Related LinksN/A